Dermatology Times Newsletter

To view this email as a web page, click here.

Read these psoriasis stories you might have missed, and connect with us on Twitter and Facebook for daily updates.

PsO treatment goals

Are your psoriasis patients satisfied with their current treatment? While several new therapies have ushered in an era of improved disease control, patient-reported outcomes still suggest failure to meet treatment goals.

Optimal levels of ustekinumab

Researchers found a significant inverse correlation between ustekinumab levels and PASI scores at week 52, suggesting that drug levels are associated with the change in the treatment response. Measuring ustekinumab levels can have major clinical implications.

Consider more than severity, spread in PsO

Why does the distinction between localized and activated disease matter? The authors state that differentiating between the two types of immune reactivity help to further define systemic inflammation in psoriasis beyond the mild and moderate-to-severe forms of the disease.

Rosacea review: what do we, and don’t we, know?

We've come a long way in our understanding of rosacea. But what remains a mystery? Part of a case study series, this podcast takes a deep dive into the pathophysiology and treatment of rosacea defined as a chronic inflammatory dermatosis.

Listen now.

From our Latest Issue

Psychodermatology: Where the skin and mind meet

Does FDA have jurisdiction over my comments?

The case for hackathons in dermatology

JOB OPPORTUNITIES

CA - Integrated Dermatology

CO-Integrated Dermatology

CT - Integrated Dermatology

District of Columbia-Integrated Dermatology

MA - Integrated Dermatology

MD - Integrated Dermatology

MS - Integrated Dermatology

National - Integrated Dermatology

NJ - Integrated Dermatology

NJ - Practice for Sale

NV - Integrated Dermatology

VA - Integrated Dermatology

VT - Integrated Dermatology

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.